90Y和177Lu-PRRT的剂量与毒性及肿瘤缓解的相关性为通过个体化治疗计划优化提供依据
作者认为多项研究提示实施剂量学可减少严重毒性和/或减少治疗不足,但需前瞻性、可能多中心、更大样本量且方法标准化的试验来确立有效的个体化PRRT预测范式。
要点
- 多项研究提示实施剂量学对PRRT有临床获益,可能减少严重毒性和/或减少治疗不足。
- 作者提出需前瞻性、可能多中心、更大样本量且方法标准化的试验来确立个体化PRRT预测范式。
核心结论
- 多项研究提供了在PRRT中实施剂量学可带来临床获益的证据,提示该做法可能有助于减少严重毒性和/或减少常见的治疗不足。
- 应开展前瞻性、可能多中心、纳入更多接受定量剂量学患者且方法标准化的试验,以最终提供稳健的预测范式来建立有效的个体化PRRT。
研究设计与样本
- 综述:检索MEDLINE数据库并组合特定关键词,纳入报告PRRT患者剂量-效应结局的英文原始研究。
主要发现
- 研究按相关性的强项与弱项进行分析和讨论。
关键数值与推荐
- 多项研究显示剂量学实施与减少严重毒性和/或减少治疗不足相关。
临床怎么用
- 作者认为,实施剂量学优化PRRT具有临床获益证据,可能减少严重毒性和/或减少治疗不足。
- 作者提出应开展前瞻性、可能多中心、更大样本量且方法标准化的试验来确立个体化PRRT的预测范式。
局限性
- 原文指出该策略尚未应用于常规临床实践。
- 作者提出需前瞻性、可能多中心、更大样本量且方法标准化的试验来最终提供稳健的预测范式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with 90Y-labelled and 177Lu-labelled peptides is an effective strategy for the treatment of metastatic/nonresectable neuroendocrine tumours (NETs). Dosimetry provides important information useful for optimizing PRRT with individualized regimens to reduce toxicity and increase tumour responses. However, this strategy is not applied in routine clinical practice, despite the fact that several dosimetric studies have demonstrated significant dose-effect correlations for normal organ toxicity and tumour response that can better guide therapy planning. The present study reviews the key relationships and the radiobiological models available in the literature with the aim of providing evidence that optimization of PRRT is feasible through the implementation of dosimetry. METHODS: The MEDLINE database was searched combining specific keywords. Original studies published in the English language reporting dose-effect outcomes in patients treated with PRRT were chosen. RESULTS: Nine of 126 studies were selected from PubMed, and a further five were added manually, reporting on 590 patients. The studies were analysed and are discussed in terms of weak and strong elements of correlations. CONCLUSION: Several studies provided evidence of clinical benefit from the implementation of dosimetry in PRRT, indicating the potential contribution of this approach to reducing severe toxicity and/or reducing undertreatment that commonly occurs. Prospective trials, possibly multicentre, with larger numbers of patients undergoing quantitative dosimetry and with standardized methodologies should be carried out to definitively provide robust predictive paradigms to establish effective tailored PRRT.
引用
- Cremonesi M, Ferrari ME, Bodei L, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785514. doi:10.1007/s00259-018-4044-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。